»
Side Effects of Drugs Annual
 
 

Side Effects of Drugs Annual, 1st Edition

A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions

 
Side Effects of Drugs Annual, 1st Edition,Jeffrey K. Aronson,ISBN9780444519863
 
 
 

Side Effects of Drugs Annual

J Aronson   

Elsevier Science

9780444519863

9780080522814

714

240 X 165

Print Book + eBook

USD 486.00
USD 810.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 420.00

eBook
eBook Overview

VST (VitalSource Bookshelf) format

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

USD 390.00
Add to Cart
 
 

Key Features

  • Provides a critical yearly survey of new data and trends
  • Includes an essay that describes the modern approach to classifying adverse drug reactions
  • Special reviews in this Annual include, among other topics: Antipsychotic drugs and now-onset diabetes mellitus, Treating asthma during pregnancy, and MMR vaccine and autism

Description

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the Annuals by selecting critically from each year's writing all that is truly new and informative, by critically interpreting it, and by pointing to whatever is misleading.

Readership

Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, Clinical pharmacologists, and medical libraries

Jeffrey K. Aronson

MA DPhil MBChB FRCP FBPharmacolS FFPM(Hon)

Dr Jeffrey K. Aronson is a consultant clinical pharmacologist and physician in the Department of Primary Health Care in the University of Oxford and a consultant physician in the Oxford Radcliffe Hospitals Trust. He has been associated with the Meyler series since 1977 and has published many research papers on adverse drug reactions. He is President of the British Pharmacological Society and serves on many committees concerned with drug therapy, including the Technology Appraisal Committee of the UK’s National Institute for Health and Clinical Excellence (NICE) and the Joint Formulary Committees of the British National Formulary and the British National Formulary for Children.

Affiliations and Expertise

Department of Primary Health Care, University of Oxford, Oxford, UK

View additional works by Jeffrey K. Aronson

Side Effects of Drugs Annual, 1st Edition

Contributors

Special reviews

Cumulative index of special reviews, Annuals 14-28

Table of Essays, Annuals 1-28

DoTS classification of adverse drug reactions

How to use this book

Data mining in drug safety

1 Central nervous system stimulants and drugs that suppress appetite

Methylxanthines (SEDA-26, 1; SEDA-27, 1; SEDA-28, 1)

Amphetamines (SED-15, 180; SEDA-26, 30; SEDA-27, 29; SEDA-28, 4, 28)

Drugs that suppress appetite (SEDA-26, 6; SEDA-27, 4; SEDA-28, 6)

Drugs used in Alzheimer's disease (SEDA-26, 7; SEDA-27, 7; SEDA-28, 9)

2 Antidepressant drugs

Mania as an adverse effect of antidepressants

Monoamine oxidase inhibitors (SED-15, 2371; SEDA-24, 12)

Tricyclic antidepressants (SED-15, 3489; SEDA-26, 11; SEDA-27, 11; SEDA-28, 15)

Selective serotonin re-uptake inhibitors (SSRIs) (SED-15, 3109; SEDA-26, 11; SEDA-27, 12; SEDA-28, 15)

Serotonin and noradrenaline re-uptake inhibitors (SNRIs)

Other antidepressants

3 Lithium

4 Drugs of abuse

Cannabinoids (SED-15, 614; SEDA-26, 36; SEDA-27, 32; SEDA-28, 36)

Cocaine (SED-15, 848; SEDA-26, 27; SEDA-27, 33; SEDA-28, 38; see also Chapter 11)

Opioid analgesics (SED-15, 2619; SEDA-27, 38; SEDA-28, 44)

5 Hypnosedatives and anxiolytics

Azaspirones (SEDA-26, 49; SEDA-27, 43; SEDA-28, 52)

Benzodiazepines (SED-15, 429; SEDA-26, 46; SEDA-27, 43; SEDA-28, 52)

Other hypnotics and sedatives

6 Antipsychotic drugs

General (SED-15, 2438)

Individual drugs

7 Antiepileptic drugs

8 Opioid analgesics and narcotic antagonists

Opioid receptor agonists

Partial opioid receptor agonists

Opioid receptor antagonists

Miscellaneous compounds

9 Anti-inflammatory and antipyretic analgesics and drugs used in gout

Coxibs and cardiovascular disease

Individual drugs and classes

Arylalkanoic acid derivatives (SED-15, 2555; SEDA-26, 115; SEDA-27, 115; SEDA-28, 126)

Oxicams (SEDA-15, 2555; SEDA-27, 116; SEDA-28, 128)

Drugs used in the treatment of gout

10 General anesthetics and therapeutic gases

Sedation in special circumstances

Anesthetic vapors (SED-15, 1489; SEDA-26, 132; SEDA-27, 119; SEDA-28, 139)

Nitrous oxide (SED-15, 2550; SEDA-27, 120; SEDA-28, 140)

Xenon (SED-15, 3693; SEDA-27, 120; SEDA-28, 140)

Intravenous agents. Miscellaneous non-barbiturate anesthetics

11 Local anesthetics

General topics (SED-15, 2116)

Effects related to modes of use (SED-15, 2121)

Individual compounds

12 Neuromuscular blocking agents and skeletal muscle relaxants

Anaphylaxis due to neuromuscular blocking agents

Skeletal muscle relaxants (SEDA-26, 152; SEDA-27, 141; SEDA-28, 157)

13 Drugs that affect autonomic functions or the extrapyramidal system

Drugs that stimulate both alpha- and beta-adrenoceptors (SEDA-26, 156; SEDA-27, 145; SEDA-28, 160)

Drugs that predominantly stimulate alpha1-adrenoceptors (SEDA-26, 157; SEDA-27, 147; SEDA-28, 161)

Drugs that stimulate beta1-adrenoceptors (SEDA-26, 159; SEDA-27, 147)

Drugs that stimulate dopamine receptors (SEDA-26, 159; SEDA-27, 148; SEDA-28, 162)

Other drugs that increase dopamine activity (SEDA-26, 162; SEDA-27, 151; SEDA-28, 164)

Drugs that affect the cholinergic system (SEDA-26, 164; SEDA-27, 152; SEDA-28, 165)

14 Dermatological drugs, topical agents, and cosmetics

Contact allergens

Photochemotherapy (SED-15, 2823; SEDA-28, 171)

Vitamin A (Retinoids) (SED-15, 3653; SEDA-27, 159; SEDA-28, 171; for vitamin A carotenoids see Chapter 34)

15 Antihistamines (H1 receptor antagonists)

16 Drugs acting on the respiratory tract

Inhaled glucocorticoids (SED-15, 958; SEDA-26, 186; SEDA-27, 174; SEDA-28, 184)

Beta2-adrenoceptor agonists (SED-15, 448; SEDA-26, 190; SEDA-27, 179; SEDA-28, 188)

Anticholinergic drugs (SED-15, 264; SEDA-26, 194; SEDA-27, 180; SEDA-28, 190)

Leukotriene modifiers (SED-15, 2025; SEDA-26, 193; SEDA-27, 177; SEDA-28, 191)

Combinations of drugs

17 Positive inotropic drugs and drugs used in dysrhythmias

Cardiac glycosides (SED-15, 648; SEDA-26, 198; SEDA-27, 185; SEDA-28, 196)

Other positive inotropic drugs (SED-15, 2822; SEDA-26, 201; SEDA-27, 188; SEDA-28, 199)

Drugs used in dysrhythmias

18 Beta-adrenoceptor antagonists and antianginal drugs

Beta-adrenoceptor antagonists (SED-15, 452; SEDA-26, 223; SEDA-27, 203; SEDA-28, 217)

Nitrates, organic (SED-15, 2529; SEDA-26, 224; SEDA-27, 204; SEDA-28, 218)

Calcium channel blockers (SED-15, 598; SEDA-26, 225; SEDA-27, 224; SEDA-28, 218)

19 Drugs acting on the cerebral and peripheral circulations

Drugs used in the treatment of arterial disorders of the brain and limbs

Drugs used in the treatment of venous disorders

Drugs used in the treatment of migraine

Other peripheral vasodilators

20 Antihypertensive drugs

Moving targets and patterns of prescribing

Angiotensin converting enzyme inhibitors (SED-15, 226; SEDA-26, 234; SEDA-27, 213; SEDA-28, 227)

Angiotensin II receptor antagonists (SED-15, 223; SEDA-26, 236; SEDA-27, 214; SEDA-28, 229)

Endothelin receptor antagonists (SED-15, 1215; SEDA-26, 233; SEDA-27, 214)

Drugs that act on the sympathetic nervous system (SEDA-27, 216; SEDA-28, 230)

Imidazoline receptor antagonists

Direct vasodilators

21 Diuretics

Hyponatremia and loop and thiazide diuretics

Urinary tract

Carbonic anhydrase inhibitors (SED-15, 643; SEDA-26, 238; SEDA-27, 220; SEDA-28, 233)

Thiazide diuretics (SED-15, 3375; SEDA-26, 239; SEDA-27, 220; SEDA-28, 233)

Loop diuretics (SED-15, 567, 1454; SEDA-26, 239; SEDA-27, 220; SEDA-28, 233)

Aldosterone receptor antagonists

Osmotic diuretics

22 Metals

23 Metal antagonists

Iron chelators

Penicillamine and related drugs

Polystyrene sulfonates (SED-15, 2894; SEDA-26, 256; SEDA-27, 236; SEDA-28, 259)

24 Antiseptic drugs and disinfectants

Bisbiguanides

Iodophors (SEDA-15, 1896; SEDA-27, 240; SEDA-28, 262)

25 Penicillins, cephalosporins, other beta-lactam antibiotics, and tetracyclines

Antimicrobial drug resistance: a serious adverse effect exemplified by avoparcin and vancomycin-resistant enterococci

Beta-lactam antibiotics (SED-15, 478; SEDA-26, 279; SEDA-27, 242; SEDA-28, 267)

Carbapenems (SED-15, 638; SEDA-26, 265; SEDA-27, 246)

Cephalosporins (SED-15, 688; SEDA-26, 264; SEDA-27, 245; SEDA-28, 268)

Monobactams (SED-15, 2378; SEDA-27, 247)

Penicillins (SED-15, 2756; SEDA-26, 262; SEDA-27, 244)

Tetracyclines (SED-15, 3330; SEDA-26, 265; SEDA-27, 247; SEDA-28, 270)

Glycylcyclines

26 Miscellaneous antibacterial drugs

Aminoglycoside antibiotics (SED-15, 118; SEDA-26, 271; SEDA-27, 251; SEDA-28, 274)

Chloramphenicol and related drugs (SED-15, 706; SEDA-26, 273; SEDA-26, 274; SEDA-26, 276)

Fluoroquinolones (SED-15, 1396; SEDA-26, 274; SEDA-27, 254; SEDA-28, 276)

Fusidic acid (SED-15, 1460; SEDA-26, 281; SEDA-27, 259; SEDA-28, 280)

Glycopeptides (SEDA-26, 281; SEDA-27, 259; SEDA-28, 280)

Ketolides (SED-15, 1976; SEDA-26, 283; SEDA-27, 260; SEDA-28, 281)

Lincosamides (SED-15, 2063; SEDA-26, 283; SEDA-27, 260; SEDA-28, 281)

Macrolide antibiotics (SED-15, 2183; SEDA-26, 284; SEDA-27, 261; SEDA-28, 282)

Nitrofurantoin (SED-15, 2542; SEDA-26, 288; SEDA-27, 264; SEDA-28, 284)

Oxazolidinones (SED-15, 2645; SEDA-26, 288; SEDA-27, 264; SEDA-28, 284)

Polymyxins (SED-15, 2891; SEDA-26, 289; SEDA-27, 265; SEDA-28, 285)

Streptogramins (SED-15, 3182; SEDA-26, 289; SEDA-27, 265; SEDA-28, 285)

Sulfonamides, trimethoprim, and co-trimoxazole (SED-15, 3216, 3510; SEDA-26, 290; SEDA-27, 266; SEDA-28, 285)

Other antimicrobial drugs

27 Antifungal drugs

Allylamines (SEDA-26, 309; SEDA-27, 284; SEDA-28, 294)

Amphotericin (SED-15, 192; SEDA-26, 302; SEDA-27, 276; SEDA-28, 295)

Antifungal azoles (SED-15, 301; SEDA-26, 304; SEDA-27, 278; SEDA-28, 299)

Echinocandins (SED-15, 1197; SEDA-26, 311; SEDA-28, 309)

28 Antiprotozoal drugs

Antimalarial drugs

4-Aminoquinolines (chloroquine and congeners) (SEDA-26, 315; SEDA-27, 289; SEDA-28, 315)

Pyrimethamine and combinations (SED-15, 2984; SEDA-26, 320; SEDA-27, 293; SEDA-28, 318)

Quinine and congeners (SED-15, 3002; SEDA-26, 318; SEDA-27, 290)

Endoperoxides

Drugs used in the treatment of pneumocystis jiroveci infections (SEDA-26, 320; SEDA-27, 295; SEDA-28, 322)

29 Antiviral drugs

Drugs active against cytomegalovirus

Drugs active against herpesviruses (SEDA-26, 329; SEDA-27, 305; SEDA-28, 328)

Drugs active against hepatitis viruses

Drugs active against human immunodeficiency virus: nucleoside analogue reverse transcriptase inhibitors (NRTI) (SED-15, 2586; SEDA-26, 330; SEDA-27, 306; SEDA-28, 332)

Drugs active against human immunodeficiency virus: nucleotide analogue reverse transcriptase inhibitors

Drugs active against human immunodeficiency virus: non-nucleoside reverse transcriptase inhibitors (NNRTI) (SED-15, 2553; SEDA-27, 308; SEDA-28, 334)

Drugs active against human immunodeficiency virus: protease inhibitors (SED-15, 2965; SEDA-26, 332; SEDA-28, 335)

Drugs active against human immunodeficiency virus: inhibitors of HIV fusion

Drugs active against influenza viruses: neuraminidase inhibitors (SED-15, 2436; SEDA-26, 334; SEDA-27, 317; SEDA-28, 337)

30 Drugs used in tuberculosis and leprosy

Immune reconstitution disease

31 Antihelminthic drugs

Artemisinin derivatives (SED-15, 342; SEDA-26, 319; SEDA-27, 292; SEDA-28, 320)

Benzimidazoles (SED-15, 424; SEDA-25, 367; SEDA-26, 344; SEDA-27, 326)

32 Vaccines

Bacterial vaccines

Viral vaccines

33 Blood, blood components, plasma, and plasma products

Albumin (SED-15, 54; SEDA-28, 371)

Anticoagulant proteins (SED-15, 266; SEDA-28, 371)

Blood transfusion (SED-15, 529; SEDA-28, 369)

Blood substitutes (SEDA-28, 370)

Plasma products (SED-15, 2847)

Plasma substitutes (SEDA-26, 374; SEDA-27, 353; SEDA-28, 371)

Globulins

Coagulation proteins (SED-15, 845; SEDA-28, 375)

Erythropoietin and derivatives (SED-15, 1243)

Stem cells

34 Formulations used in nutrition

Parenteral nutrition (SED-15, 2700; SEDA-26, 377; SEDA-27, 355; SEDA-28, 383)

Vitamins of the B group (SEDA-26, 419; SEDA-27, 407; SEDA-28, 387)

Vitamin D Analogues (SED-15, 3669; SEDA-28, 388)

Vitamin E (SED-15, 3677)

35 Drugs affecting blood coagulation, fibrinolysis, and hemostasis

Coumarin anticoagulants (SED-15, 983; SEDA-26, 379; SEDA-27, 358; SEDA-28, 391)

Heparins (SED-15, 1590; SEDA-26, 379; SEDA-27, 358; SEDA-28, 391)

Thrombolytic agents (SED-15, 3402; SEDA-28, 392)

Short polysaccharide inhibitors of coagulating factors (SEDA-27, 359; SEDA-28, 392)

Direct thrombin inhibitors (SED-15, 1142; SEDA-27, 359)

Drugs that alter platelet function (SEDA-25, 412; SEDA-26, 380; SEDA-27, 360; SEDA-28, 396)

Hemostatic agents

36 Gastrointestinal drugs

Antiemetics and drugs that affect gastrointestinal motility

5-HT3 receptor antagonists (SED-15, 1365; SEDA-26, 382; SEDA-27, 363; SEDA-28, 402)

Histamine H2 receptor antagonists (SED-15, 1629; SEDA-26, 384; SEDA-27, 363; SEDA-28, 403)

Proton pump inhibitors (SED-15, 2973; SEDA-26, 384; SEDA-27, 364; SEDA-28, 403)

Antidiarrheal agents (SEDA-27, 367; SEDA-28, 406)

Laxatives and oral bowel preparations (SED-15, 2008; SEDA-26, 387; SEDA-27, 367; SEDA-28, 406)

Aminosalicylates (SED-15, 138; SEDA-26, 387; SEDA-27, 367; SEDA-28, 408)

Bile acids (SED-15, 515; SEDA-26, 389; SEDA-27, 369; SEDA-28, 409)

Prebiotics

Other gastrointestinal agents

37 Drugs that act on the immune system: cytokines and monoclonal antibodies

Colony-stimulating factors (SEDA-26, 398; SEDA-27, 391; SEDA-28, 415)

Interferons (SED-15, 1841; SEDA-26, 393; SEDA-27, 383; SEDA-28, 416)

Interleukins (SED-15, 1842; SEDA-26, 397; SEDA-27, 390; SEDA-28, 424)

Tumor necrosis factor (TNF) antagonists (SEDA-26, 399; SEDA-27, 393; SEDA-28, 425)

Monoclonal antibodies (SED-15, 2380; SEDA-26, 402; SEDA-27, 378; SEDA-28, 434)

38 Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs

Immunosuppressive drugs

Immunoenhancing drugs

Other drugs

39 Corticotrophins, corticosteroids, and prostaglandins

Systemic glucocorticoids (SED-15, 906; SEDA-26, 427; SEDA-27, 414; SEDA-28, 471)

Nasal glucocorticoids

Intra-articular glucocorticoids

Prostaglandins and analogues (SED-15, 2955; SEDA-26, 430; SEDA-27, 417; SEDA-28, 476)

40 Sex hormones and related compounds, including hormonal contraceptives

Gonadotropins and ovulation-inducing drugs (SED-15, 1536; SEDA-26, 434; SEDA-27, 420; SEDA-28, 480)

Estrogens (SED-15, 1253; SEDA-26, 436; SEDA-27, 422; SEDA-28, 481)

Hormonal contraceptives (SED-15, 1642 et seq; SEDA-26, 442; SEDA-27, 426; SEDA-28, 487)

Antiestrogens and selective estrogen receptor modulators (SERMs) (SEDA-26, 445; SEDA-27, 429; SEDA-28, 490)

Progestogens (SED-15, 2930; SEDA-26, 447; SEDA-27, 433; SEDA-28, 493)

Progesterone antagonists (SEDA-26, 448; SEDA-27, 433; SEDA-28, 494)

Anabolic steroids, androgens, and related compounds (SED-15, 216; SEDA-26, 449; SEDA-27, 434; SEDA-28, 495)

Antiandrogens (SEDA-26, 451; SEDA-27, 435; SEDA-28, 497)

Miscellaneous compounds

41 Thyroid hormones and antithyroid drugs

THYROID HORMONES (SED-15, 3409; SEDA-26, 45; SEDA-27, 442; SEDA-28, 505)

Antithyroid drugs (SED-15, 3387; SEDA-26, 458; SEDA-27, 442; SEDA -28, 506)

42 Insulin, other hypoglycemic drugs, and glucagon

Insulin (SED-15, 1761; SEDA-26, 461; SEDA-27, 446; SEDA-28, 509)

New ultrashort-acting insulins (SEDA-26, 463; SEDA-27, 449; SEDA-28, 512)

Long-acting insulins (SEDA-26, 463; SEDA-27, 450; SEDA-28, 513)

Alpha glucosidase inhibitors (SED-15, 85; SEDA-26, 466; SEDA-27, 452; SEDA-28, 514)

Amylin analogues (SEDA-27, 453; SEDA-28, 514)

Biguanides (SED-15, 506; SEDA-26, 467; SEDA-27, 453; SEDA-28, 514)

Meglitinides (SED-15, 2238; SEDA-26, 468; SEDA-27, 455; SEDA-28, 518)

Sulfonylureas (SED-15, 3230; SEDA-26, 469; SEDA-27, 456; SEDA-28, 518)

Thiazolidinediones (glitazones) (SED-15, 3380; SEDA-26, 471; SEDA-27, 457; SEDA-28, 519)

Combinations of oral hypoglycemic drugs

43 Miscellaneous hormones

Somatostatin (growth hormone release-inhibiting hormone) and analogues (SED-15, 3160; SEDA-26, 480; SEDA-27, 467; SEDA-28, 530)

Vasopressin and analogues (SED-15, 3609; SEDA-26, 482; SEDA-27, 469; SEDA-28, 531)

44 Drugs that affect lipid metabolism

45 Cytostatic drugs

General

46 Radiological contrast agents

Types of contrast agents

MRI contrast media

47 Drugs used in ocular treatment

Intravitreal and parabulbar injection of drugs

Ocular dyes

48 Treatments used in complementary and alternative medicine

Herbal medicines (SED-15, 1609; SEDA-26, 528; SEDA-27, 512; SEDA-28, 573)

Non-herbal supplements

Acupuncture (SED-15, 890; SEDA-26, 535; SEDA-27, 520; SEDA-28, 581)

Colonic irrigation

Homeopathy (SED-15, 892; SEDA-28, 582)

Spinal manipulation (SED-15, 893; SEDA-26, 536; SEDA-27, 521; SEDA-28, 582)

49 Miscellaneous drugs and materials, medical devices, and techniques

Dyestuffs

Medical devices

49 Miscellaneous drugs and materials, medical devices, and techniques

Address list of national centres that participate in the WHO Drug Monitoring Programme

Index of drugs

Index of adverse effects

 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us